MiMedx Group Inc
NASDAQ:MDXG

Watchlist Manager
MiMedx Group Inc Logo
MiMedx Group Inc
NASDAQ:MDXG
Watchlist
Price: 7.22 USD 0.84%
Market Cap: 1.1B USD

EV/EBITDA
Enterprise Value to EBITDA

14.3
Current
17.1
Median
6.4
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
14.3
=
Enterprise Value
943.9m USD
/
EBITDA
66.2m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
MiMedx Group Inc
NASDAQ:MDXG
Average EV/EBITDA: 36.4
14.3
27%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
NL
argenx SE
XBRU:ARGX
56.7
839%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
hidden
2-Years Forward
EV/EBITDA
hidden
3-Years Forward
EV/EBITDA
hidden